Skip to main content
Fig. 6 | Breast Cancer Research

Fig. 6

From: CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance

Fig. 6

Everolimus has synergistic antiproliferative activity with T-DM1 Combination indices of antiproliferative activity of T-DM1 and everolimus. Everolimus (EVL) was tested at different concentrations to cause 20–80% inhibition of cell growth. Average indicates the average combination index across all five everolimus concentrations. Symbols represent the mean ± SEM of n = 2–4. The green box indicates synergy with combination index < 0.9

Back to article page